BidaskClub upgraded shares of Inogen (NASDAQ:INGN) from a buy rating to a strong-buy rating in a research report report published on Friday.
A number of other brokerages have also weighed in on INGN. Zacks Investment Research lowered shares of Inogen from a buy rating to a hold rating in a report on Wednesday, February 7th. Needham & Company LLC reiterated a buy rating and issued a $150.00 price target on shares of Inogen in a report on Tuesday, March 27th. Piper Jaffray upgraded shares of Inogen from a neutral rating to an overweight rating in a report on Tuesday, February 20th. Finally, ValuEngine upgraded shares of Inogen from a hold rating to a buy rating in a report on Friday. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $107.29.
INGN stock traded down $2.40 during midday trading on Friday, hitting $128.00. The stock had a trading volume of 138,117 shares, compared to its average volume of 122,995. The stock has a market capitalization of $2,766.28, a P/E ratio of 97.71, a PEG ratio of 3.63 and a beta of 1.03. Inogen has a 12-month low of $74.06 and a 12-month high of $134.97.
Inogen (NASDAQ:INGN) last released its earnings results on Tuesday, February 27th. The medical technology company reported $0.31 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.21 by $0.10. The firm had revenue of $63.79 million during the quarter, compared to analysts’ expectations of $62.01 million. Inogen had a net margin of 8.42% and a return on equity of 13.47%. equities analysts anticipate that Inogen will post 1.6 earnings per share for the current year.
In related news, EVP Matt Scribner sold 2,500 shares of Inogen stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $116.17, for a total transaction of $290,425.00. Following the transaction, the executive vice president now owns 7,297 shares in the company, valued at approximately $847,692.49. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Scott Wilkinson sold 30,651 shares of Inogen stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $115.75, for a total transaction of $3,547,853.25. Following the transaction, the insider now owns 38,107 shares in the company, valued at approximately $4,410,885.25. The disclosure for this sale can be found here. In the last quarter, insiders sold 158,369 shares of company stock worth $18,919,065. 5.31% of the stock is owned by company insiders.
Several large investors have recently bought and sold shares of the stock. MetLife Investment Advisors LLC acquired a new position in shares of Inogen during the 4th quarter valued at $957,000. Gotham Asset Management LLC acquired a new position in shares of Inogen during the 4th quarter valued at $863,000. Jane Street Group LLC acquired a new position in shares of Inogen during the 4th quarter valued at $243,000. Meadow Creek Investment Management LLC lifted its holdings in shares of Inogen by 26.0% during the 4th quarter. Meadow Creek Investment Management LLC now owns 2,576 shares of the medical technology company’s stock valued at $307,000 after acquiring an additional 532 shares in the last quarter. Finally, Raymond James & Associates acquired a new position in shares of Inogen during the 4th quarter valued at $244,000. Institutional investors and hedge funds own 99.49% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/07/inogen-ingn-rating-increased-to-strong-buy-at-bidaskclub.html.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.